title: [Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk].
abstract: The consequences to the bone of estrogen deficiency are early and irreversible. Effective prevention of postmenopausal osteoporosis at the individual level requires early screening of women at risk of fractures and their early treatment. Hormone treatment prevents bone loss and has been proven effective in preventing fractures, even in situations of low risk. The benefit/risk ratio of hormone treatment can be optimized by the choice of the 'right moment' and the 'right treatment'. HRT, administered early and for a limited period, must be integrated into a strategy of long-term osteoporosis prevention that includes using the (drug and nondrug) means most appropriate to the patient's age and clinical condition and choosing the 'right moment' and 'right treatment.'
authors.affiliation: Unité ménopause et maladies osseuses métaboliques, Hôpital Paule de Viguier, Toulouse (31). ribot.c@chu-toulouse.fr
authors.forename: Claude
authors.initials: C
authors.lastname: Ribot
authors.forename: Florence
authors.initials: F
authors.lastname: Trémollières
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000139:chemically induced; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D005264:Femoral Fractures / Q000517:prevention & control; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D016103:Spinal Fractures / Q000517:prevention & control; D020521:Stroke / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced; D013997:Time Factors; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D011372:Progestins; D004958:Estradiol